Impact of the definition of time to event endpoint on randomized clinical trials results in oncology (datecan-2): an analysis of 9 pancreatic cancer trials

被引：0
|
作者：
Pam, A. [1 ]
Vernerey, D. [1 ]
Baron, B. [2 ]
Chauffert, B. [3 ]
Louvet, C. [4 ]
Wagener, J. [5 ]
Levi, F. [6 ,7 ]
Hans, S. [8 ]
Trouilloud, I. [9 ]
Jan, J. [10 ]
Van Laethem, J. L. [11 ]
Taieb, J. [9 ]
Haustermans, K. [12 ]
Dahan, L. [13 ]
Dureux, M. [14 ]
Lutz, M. [15 ]
Bellera, C. [16 ]
Gourgou, S. [17 ,18 ]
Anota, A. [1 ]
Bonnetain, F. [1 ]
机构：
[1] CHU Besancon, Doubs, F-25030 Besancon, France
[2] EORTC Data Ctr, Brussels, Belgium
[3] Anticanc Ctr GF Leclerc, Dept Oncol, Dijon, France
[4] Inst Mutualiste Montsouris, Dept Oncol, Paris, France
[5] UMC Nijmegen, Nijmegen, Netherlands
[6] Hop Paul Brousse, Villejuif, France
[7] INSERM, Villejuif, France
[8] Univ Hosp Rotterdam Dijikzigt, Rotterdam, Netherlands
[9] Georges Pompidou European Hosp, Dept Gastroenterol & Digest Oncol, Paris, France
[10] Univ Rotterdam Hosp, Rotterdam, Netherlands
[11] Erasme Univ Hosp, Medicosug Dept Gastroenerol, B-1070 Brussels, Belgium
[12] Univ Hosp Gasthuisberg, Leuven, Leuven, Belgium
[13] Univ Mediterranean, Timone Hosp, Hosp Publ Assistance Marseille, Marseille, France
[14] Inst Gustave Roussy, Gastrointestinal Unit, Villejuif, France
[15] Univ Ulm, D-89069 Ulm, Germany
[16] Inst Bergonie, Ctr Comprehens Canc, Clin & Epidemiol Res Unit, Bordeaux, France
[17] Inst Canc Montpellier, Ctr Comprehens Canc, Montpellier, France
[18] Data Ctr Canc Clin Trials, CTD INCa, Montpellier, France
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)31292-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2376
引用
收藏
页码：S462 / S462
页数：1
相关论文
共 50 条
  • [21] Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative
    Cohen, Romain
    Vernerey, Dewi
    Bellera, Carine
    Meurisse, Aurelia
    Henriques, Julie
    Paoletti, Xavier
    Rousseau, Benoit
    Alberts, Steven
    Aparicio, Thomas
    Boukovinas, Ioannis
    Gill, Sharlene
    Goldberg, Richard M.
    Grothey, Axel
    Hamaguchi, Tetsuya
    Iveson, Timothy
    Kerr, Rachel
    Labianca, Roberto
    Lonardi, Sara
    Meyerhardt, Jeffrey
    Paul, James
    Punt, Cornelis J. A.
    Saltz, Leonard
    Saunders, Marck P.
    Schmoll, Hans-Joachim
    Shah, Manish
    Sobrero, Alberto
    Souglakos, Ioannis
    Taieb, Julien
    Takashima, Atsuo
    Wagner, Anna Dorothea
    Ychou, Marc
    Bonnetain, Franck
    Gourgou, Sophie
    Yoshino, Takayuki
    Yothers, Greg
    de Gramont, Aimery
    Shi, Qian
    Andre, Thierry
    EUROPEAN JOURNAL OF CANCER, 2020, 130 : 63 - 71
  • [22] Disease-free survival as a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a meta-analysis of 20 randomized controlled trials
    Run-Cong Nie
    Xue-Bin Zou
    Shu-Qiang Yuan
    Ying-Bo Chen
    Shi Chen
    Yong-Ming Chen
    Guo-Ming Chen
    Xiao-Jiang Chen
    Tian-Qi Luo
    Shu-Man Li
    Jin-Ling Duan
    Yun Wang
    Yuan-Fang Li
    BMC Cancer, 20
  • [23] Disease-free survival as a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a meta-analysis of 20 randomized controlled trials
    Nie, Run-Cong
    Zou, Xue-Bin
    Yuan, Shu-Qiang
    Chen, Ying-Bo
    Chen, Shi
    Chen, Yong-Ming
    Chen, Guo-Ming
    Chen, Xiao-Jiang
    Luo, Tian-Qi
    Li, Shu-Man
    Duan, Jin-Ling
    Wang, Yun
    Li, Yuan-Fang
    BMC CANCER, 2020, 20 (01)
  • [24] From Logic-Respecting Efficacy Estimands to Logic-Ensuring Analysis Principle for Time-to-Event Endpoint in Randomized Clinical Trials with Subgroups
    Liu, Yi
    Yang, Miao
    Kil, Siyoen
    Li, Jiang
    Mondal, Shoubhik
    Shentu, Yue
    Tian, Hong
    Wang, Liwei
    Yung, Godwin
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2023, 15 (03): : 560 - 573
  • [25] A Meta-analysis of Randomized Clinical Trials of Chemoradiation Therapy in Locally Advanced Pancreatic Cancer
    Ambe C.
    Fulp W.
    Springett G.
    Hoffe S.
    Mahipal A.
    Journal of Gastrointestinal Cancer, 2015, 46 (3) : 284 - 290
  • [26] Approaches to interim analysis of cancer randomised clinical trials with time to event endpoints: A survey from the Italian National Monitoring Centre for Clinical Trials
    Floriani, Irene
    Rotmensz, Nicole
    Albertazzi, Elena
    Torri, Valter
    De Rosa, Marisa
    Tomino, Carlo
    de Braud, Fillipo
    TRIALS, 2008, 9 (1)
  • [27] Approaches to interim analysis of cancer randomised clinical trials with time to event endpoints: A survey from the Italian National Monitoring Centre for Clinical Trials
    Irene Floriani
    Nicole Rotmensz
    Elena Albertazzi
    Valter Torri
    Marisa De Rosa
    Carlo Tomino
    Fillipo de Braud
    Trials, 9
  • [28] Sensitivity Analysis of Per-Protocol Time-to-Event Treatment Efficacy in Randomized Clinical Trials
    Gilbert, Peter B.
    Shepherd, Bryan E.
    Hudgens, Michael G.
    JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 2013, 108 (503) : 789 - 800
  • [29] Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254
    Thanarajasingam, Gita
    Atherton, Pamela J.
    Novotny, Paul J.
    Loprinzi, Charles L.
    Sloan, Jeff A.
    Grothey, Axel
    LANCET ONCOLOGY, 2016, 17 (05): : 663 - 670
  • [30] Surrogate marker analysis in cancer clinical trials through time-to-event mediation techniques
    Vandenberghe, Sjouke
    Duchateau, Luc
    Slaets, Leen
    Bogaerts, Jan
    Vansteelandt, Stijn
    STATISTICAL METHODS IN MEDICAL RESEARCH, 2018, 27 (11) : 3367 - 3385
12345